Renovorx, Inc.

RNXT · Nasdaq · ·

Karşılaştır

$1,05-%9,913 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 5 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: -%7,5
1M: -%6,7

Just reported

Q3 2026 results

From Renovorx's results release of 5 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$1,1M
+%301 y/y
+%17 q/q
Guided
—
No guide given
EPS, GAAP
Actual
-$0,08
Guided
—
No guide given
Operating income, GAAP
Actual
-$3,2M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$3,75M – $4,25M+%256 y/y Raised +%14

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Renovorx is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Renovorx, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Renovorx, Inc.

Renovorx, Inc.

Q3 2026 results

Revenue

EPS, GAAP